ZA201008303B - Methods for treating neurodegenerative disorders related to neurofibrillary tangles. - Google Patents

Methods for treating neurodegenerative disorders related to neurofibrillary tangles.

Info

Publication number
ZA201008303B
ZA201008303B ZA2010/08303A ZA201008303A ZA201008303B ZA 201008303 B ZA201008303 B ZA 201008303B ZA 2010/08303 A ZA2010/08303 A ZA 2010/08303A ZA 201008303 A ZA201008303 A ZA 201008303A ZA 201008303 B ZA201008303 B ZA 201008303B
Authority
ZA
South Africa
Prior art keywords
methods
neurodegenerative disorders
disorders related
neurofibrillary tangles
treating neurodegenerative
Prior art date
Application number
ZA2010/08303A
Other languages
English (en)
Inventor
Nikolaos Tezapsidis
Steven Greco
Mark Smith
Original Assignee
Neurotez Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotez Inc filed Critical Neurotez Inc
Publication of ZA201008303B publication Critical patent/ZA201008303B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2010/08303A 2008-05-21 2010-11-19 Methods for treating neurodegenerative disorders related to neurofibrillary tangles. ZA201008303B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5500908P 2008-05-21 2008-05-21
PCT/US2009/044907 WO2009143380A2 (en) 2008-05-21 2009-05-21 Methods for treating progressive cognitive disorders related to neurofibrillary tangles

Publications (1)

Publication Number Publication Date
ZA201008303B true ZA201008303B (en) 2012-04-25

Family

ID=41340901

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/08303A ZA201008303B (en) 2008-05-21 2010-11-19 Methods for treating neurodegenerative disorders related to neurofibrillary tangles.

Country Status (9)

Country Link
US (2) US8642543B2 (enExample)
EP (1) EP2326339A4 (enExample)
JP (1) JP5622720B2 (enExample)
KR (1) KR20110028457A (enExample)
CN (1) CN102099048A (enExample)
AU (1) AU2009248914A1 (enExample)
CA (1) CA2725143A1 (enExample)
WO (1) WO2009143380A2 (enExample)
ZA (1) ZA201008303B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
KR20110028457A (ko) * 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
EP2352510A4 (en) * 2008-11-04 2012-08-29 Neurotez Inc LEPTIN COMPOSITIONS AND METHODS OF TREATING PROGRESSIVE COGNITIVE DISORDERS DUE TO THE ASSEMBLY OF NEUROFIBRILLARY BUNNELS AND AMYLOID BETA
EP3620154A1 (en) * 2009-02-06 2020-03-11 University Of Southern California Therapeutic compositions comprising monoterpenes
EP3769754A1 (en) 2010-03-03 2021-01-27 Neonc Technologies, Inc. Pharmaceutical compositions comprising monoterpenes
EP2883543B1 (en) 2010-08-27 2016-11-16 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol carbamates
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
EP4656641A2 (en) 2010-12-17 2025-12-03 University of Southern California Methods and devices for using isoperillyl alcohol
US20140088000A1 (en) * 2012-09-27 2014-03-27 Neurotez, Inc. Leptin Rescues Neurons from Alzheimer's Disease Related Pathways Triggered by Lipid Burden
WO2014165043A1 (en) * 2013-03-13 2014-10-09 Neurotez, Inc. Fragments, mutants and chimeric fusion proteins of leptin for treating alzheimer's disease
AU2016219257B2 (en) 2015-02-12 2020-06-25 University Of Southern California Pharmaceutical compositions comprising perillyl alcohol derivatives
JP7144411B2 (ja) 2016-11-30 2022-09-29 ネオンク テクノロジーズ インク． ペリリルアルコール－３－ブロモピルベート複合体及びがんの治療方法
CN111936125B (zh) 2018-02-08 2025-03-04 南加州大学 穿透血脑屏障的方法
WO2020182322A1 (en) 2019-03-14 2020-09-17 Om Pharma Sa Method of treating and/or preventing asthma, asthma exacerbations, allergic asthma and/or associated conditions with microbiota related to respiratory disorders
NL2027383B1 (en) 2020-01-24 2022-04-06 Aim Immunotech Inc Methods, compositions, and vaccines for treating a virus infection
CN114958760B (zh) * 2021-02-23 2024-04-26 南京启真基因工程有限公司 一种构建阿尔兹海默症模型猪的基因编辑技术及其应用

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
AT396333B (de) 1982-10-08 1993-08-25 Glaxo Group Ltd Vorrichtung zur verabreichung von medikamenten an patienten, einrichtung mit mehreren solchen vorrichtungen und traeger mit medikamentbehaeltern hiefuer
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GR861995B (en) 1985-07-30 1986-11-04 Glaxo Group Ltd Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US20020107211A1 (en) 1995-06-07 2002-08-08 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6048837A (en) 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
FI973162L (fi) 1995-01-31 1997-09-30 Lilly Co Eli Liikalihavuutta vastustavia proteiineja
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
WO1996023514A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
EP0815230A2 (en) 1995-03-20 1998-01-07 Ligand Pharmaceuticals, Inc. MODULATORS OF ob GENE AND SCREENING METHODS THEREFOR
EP0741187A2 (en) 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Recombinant obese (Ob) proteins
CZ416797A3 (cs) 1995-06-30 1998-06-17 Eli Lilly And Company Použití leptinu nebo leptonových mimetik pro výrobu léčiv pro léčení nebo prevenci diabetes mellitus a kompozice s jeho obsahem
US5698389A (en) 1995-11-16 1997-12-16 Tularik, Inc. Transcriptional promoter of the murine obesity gene
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
CZ9802013A3 (cs) 1995-12-27 1998-09-16 Genentech, Inc. Deriváty OB proteinu, chimerní OB polypeptidy, prostředky pro léčbu obezity a dalších fyziologických stavů a způsob léčení těmito prostředky, kódující sekvence pro OB protein, expresní vektor nesoucí tuto sekvenci, buňky transformované tímto vektorem a způsob jejich kultivace, a způsob navození růstu buněk s pomocí OB proteinu
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6025324A (en) 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
US5830450A (en) 1996-06-19 1998-11-03 Lallone; Roger L. Compositions of leptin bound to an apolipoprotein
US6630346B1 (en) 1996-06-20 2003-10-07 Merck & Co., Inc. Gene therapy for obesity
CA2258504A1 (en) 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
US6001816A (en) 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US20060205660A1 (en) 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
WO1997048806A1 (en) 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
WO1998024896A2 (en) 1996-12-06 1998-06-11 F. Hoffmann-La Roche Ag Muteins of obese protein
US20020019352A1 (en) 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
US6020004A (en) 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
CN1202862C (zh) 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
EP0950417A3 (en) 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
JP4215857B2 (ja) * 1998-03-26 2009-01-28 裕 大村 学習・記憶能力改善剤
GB9807062D0 (en) 1998-04-02 1998-06-03 Imp College Innovations Ltd Immune response
DE69920921T2 (de) 1998-07-28 2006-03-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Leptin vermittelte geninduktion
ATE280588T1 (de) 1998-08-10 2004-11-15 Amgen Inc Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
CA2344623A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
CA2353776A1 (en) 1998-12-09 2000-06-15 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6716810B1 (en) 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
WO2000040615A2 (en) 1999-01-07 2000-07-13 Lexigen Pharmaceuticals, Corp. EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS
PT1151102E (pt) 1999-02-12 2006-07-31 Amgen Inc Composicoes de leptina glicosilada e metodos afins
US20030215423A1 (en) 1999-04-01 2003-11-20 Merck & Co., Inc. Gene therapy for obesity
US6475984B2 (en) 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
EP1191945A4 (en) 1999-06-11 2003-04-23 Baylor College Medicine METHODS AND COMPOSITIONS FOR CONTROLLING BONE FORMATION BY MODULATING LEPTIN ACTIVITY
AU783925B2 (en) * 1999-08-10 2005-12-22 Uab Research Foundation Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins
WO2001013935A2 (en) 1999-08-23 2001-03-01 The Administrators Of The Tulane Educational Fund Modulation of the blood-brain barrier transporter for leptin
HK1048513B (en) * 2000-01-24 2007-12-07 Fujirebio Europe N.V. Diagnosis of tauopathies determining tau/phospho-tau ratio
US7582292B2 (en) 2000-02-26 2009-09-01 Artecel, Inc. Adipose tissue derived stromal cells for the treatment of neurological disorders
MXPA04001187A (es) * 2001-08-07 2004-07-08 Immunex Corp Receptores de interleucina-1 en el tratamiento de enfermedades.
AU2002321557B2 (en) 2001-08-29 2006-03-30 The University Of Buckingham Use of leptin for infant with low birth weight for prevention of obesity
PT2219031E (pt) 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
IL162269A0 (en) 2001-12-05 2005-11-20 Baylor College Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US7642281B2 (en) 2002-08-07 2010-01-05 Helicon Therapeutics, Inc. Indolone compounds useful to treat cognitive impairment
GB0323039D0 (en) * 2003-10-01 2003-11-05 Danisco Method
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US7407929B2 (en) 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
WO2005110468A2 (en) 2004-05-10 2005-11-24 The Burnham Institute Treatment of insulin resistance/metabolic syndrome to alleviate the risks of dementia
US20050287519A1 (en) 2004-05-12 2005-12-29 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8043619B2 (en) 2004-10-08 2011-10-25 Yaron Ilan Methods and uses of leptin in immune modulation
US7307142B2 (en) 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
JP2009508847A (ja) * 2005-09-16 2009-03-05 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 栄養状態、認知および生存を改善するための化合物
EP1795895A1 (en) 2005-12-08 2007-06-13 KeyNeurotek AG A tissue-based assay system for Alzheimer-specific degeneration and pathology
US20070218504A1 (en) 2006-03-09 2007-09-20 University Of Pittsburgh Human leptin-derived polypeptides and uses thereof
WO2007139818A2 (en) 2006-05-22 2007-12-06 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
WO2008048691A2 (en) 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
WO2008115880A2 (en) 2007-03-21 2008-09-25 The Board Of Regents Of The University Of Texas System Use of leptin for the treatment or prevention of parkinson's disease
US20100267630A1 (en) 2007-06-20 2010-10-21 Universitat De Les Illes Balears Use of leptin in the prevention of unhealthy food habits and cardiovascular diseases
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
US20090031434A1 (en) 2007-07-26 2009-01-29 Weiping Han Animal models for obesity and neurodegenerative diseases
US8470772B2 (en) 2008-02-27 2013-06-25 Temple University—Of the Commonwealth System of Higher Education Leptin agonist and methods of use
US20110190215A1 (en) 2008-05-15 2011-08-04 Regen Therapeutics Plc Therapeutic use of peptides
KR20110028457A (ko) * 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
EP2352510A4 (en) 2008-11-04 2012-08-29 Neurotez Inc LEPTIN COMPOSITIONS AND METHODS OF TREATING PROGRESSIVE COGNITIVE DISORDERS DUE TO THE ASSEMBLY OF NEUROFIBRILLARY BUNNELS AND AMYLOID BETA

Also Published As

Publication number Publication date
US8642543B2 (en) 2014-02-04
WO2009143380A3 (en) 2010-01-14
JP2011520981A (ja) 2011-07-21
KR20110028457A (ko) 2011-03-18
CN102099048A (zh) 2011-06-15
JP5622720B2 (ja) 2014-11-12
US20090291894A1 (en) 2009-11-26
EP2326339A4 (en) 2012-06-20
CA2725143A1 (en) 2009-11-26
AU2009248914A1 (en) 2009-11-26
US20120010132A9 (en) 2012-01-12
EP2326339A2 (en) 2011-06-01
WO2009143380A2 (en) 2009-11-26
US20140121157A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
ZA201008303B (en) Methods for treating neurodegenerative disorders related to neurofibrillary tangles.
IL212986A0 (en) Methods for treating eye disorders
EP2310081B8 (en) System for treating psychiatric disorders
WO2010144865A9 (en) Methods for treating gastrointestinal disorders
GB2467710B (en) Methods for treating social disorders
EP2485727A4 (en) PYRROLOPYRAZOLE FOR THE TREATMENT OF CNS DISEASES
EP2331088A4 (en) COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
AP2012006188A0 (en) Bispecific binding molecules for anti-angiogenesistherapy.
DK3421603T3 (da) Genterapi for neurodegenerative forstyrrelser
IL219914A (en) In the history of 3,1-diphenylprop-2-and-1-one for the treatment of liver disorders
AP2011005824A0 (en) Methods for treating acute myocardial infarctions and associated disorders.
PL2496228T3 (pl) Sposoby leczenia zespołu nadpobudliwości psychoruchowej/deficytu uwagi
ZA201203342B (en) Treatments for gastrointestinal disorders
ZA201002167B (en) Treatment regime for proliferative disorders
IL208069A0 (en) Methods for treating psoriasis
PT2299822T (pt) Método para o tratamento da disfunção neurodegenerativa
EP2331097A4 (en) METHOD FOR TREATING CNS DISEASES
PL2317867T3 (pl) Sposób leczenia nadwrażliwych zębów
IL198856A0 (en) Compounds useful for treating neurodegenerative disorders
IL221415A0 (en) Compounds useful for treating neurodegenerative disorders
GB0809476D0 (en) Treatment of neurodegenerative disorders
ZA201009226B (en) Nifurtimox for treating disease caused by trichomonadida
SG10201401310VA (en) Method for treating immune disorders
EP2387402A4 (en) METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS WITH 2,4-PYRIMIDINIAMIN COMPOUNDS
IL207906A0 (en) Treatment for ocular-related disorders